"Rifampin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)
Below are MeSH descriptors whose meaning is more general than "Rifampin".
Below are MeSH descriptors whose meaning is more specific than "Rifampin".
This graph shows the total number of publications written about "Rifampin" by people in this website by year, and whether "Rifampin" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Rifampin" by people in Profiles.
Rifampin resistance mutations in the rpoB gene of Enterococcus faecalis impact host macrophage cytokine production. Cytokine. 2022 03; 151:155788.
Immunometabolism during Mycobacterium tuberculosis Infection. Trends Microbiol. 2020 10; 28(10):832-850.
Mycobacterium tuberculosis carrying a rifampicin drug resistance mutation reprograms macrophage metabolism through cell wall lipid changes. Nat Microbiol. 2018 10; 3(10):1099-1108.
Cellulose-based amorphous solid dispersions enhance rifapentine delivery characteristics in vitro. Carbohydr Polym. 2018 Feb 15; 182:149-158.
In Vivo Hepatic Enhancer Elements in the Human ABCG2 Locus. Drug Metab Dispos. 2017 02; 45(2):208-215.
Sequential rapid oral desensitization to rifampin and moxifloxacin for the treatment of active mycobacterium tuberculosis. J Allergy Clin Immunol Pract. 2017 Jan - Feb; 5(1):195-197.
A randomized trial comparing standard outcomes in two treatment models for substance users with tuberculosis. Int J Tuberc Lung Dis. 2015 Mar; 19(3):326-32.
Temporal interferon-gamma release response to Mycobacterium kansasii infection in an anorexia nervosa patient. J Med Microbiol. 2012 Nov; 61(Pt 11):1617-1620.
The renal failure that vanished. J Hosp Med. 2010 Jul-Aug; 5(6):371-2.
Novel polymorphic human UDP-glucuronosyltransferase 2A3: cloning, functional characterization of enzyme variants, comparative tissue expression, and gene induction. Mol Pharmacol. 2008 Sep; 74(3):744-54.